Literature DB >> 2156852

The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

N Behrendt1, E Rønne, M Ploug, T Petri, D Løber, L S Nielsen, W D Schleuning, F Blasi, E Appella, K Danø.   

Abstract

The receptor for human urokinase-type plasminogen activator (u-PA) was purified from phorbol 12-myristate 13-acetate-stimulated U937 cells by temperature-induced phase separation of detergent extracts, followed by affinity chromatography with immobilized diisopropyl fluorophosphate-treated u-PA. The purified protein shows a single 55-60 kDa band after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining. It is a heavily glycosylated protein, the deglycosylated polypeptide chain comprising only 35 kDa. The glycosylated protein contains N-acetyl-D-glucosamine and sialic acid, but no N-acetyl-D-galactosamine. Glycosylation is responsible for substantial heterogeneity in the receptor on phorbol ester-stimulated U937 cells, and also for molecular weight variations among various cell lines. The amino acid composition and the NH2-terminal amino acid sequence are reported. The protein has a high content of cysteine residues. The NH2-terminal sequence is not closely related to any known sequence. The identification of the purified and sequenced protein with the human u-PA receptor is based on the following findings: 1) the ability of the purified protein to bind u-PA and its amino-terminal fragment; 2) the identical electrophoretic mobilities observed for cross-linked conjugates, formed between either the purified protein or the u-PA receptor on intact U937 cells and the above ligands; 3) the identity of the apparent molecular weight of the purified protein to that predicted for the u-PA receptor in the same cross-linking studies; 4) the identical extent of glycosylation of the purified protein and of the u-PA receptor in crude membrane fractions, as detected after cross-linking; 5) the ability of antibodies raised against the purified protein to inhibit cellular binding of the amino-terminal fragment of u-PA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156852

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Isolation and characterization of cell lines with reduced urokinase binding.

Authors:  H K Lau; J M Teitel; M Kim
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

3.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

4.  Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.

Authors:  Anne M Brooks; Mary Ellen Bates; Rose F Vrtis; Nizar N Jarjour; Paul J Bertics; Julie B Sedgwick
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-25       Impact factor: 6.914

5.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

6.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

7.  Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells.

Authors:  S Sheng; J Carey; E A Seftor; L Dias; M J Hendrix; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

8.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

9.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Authors:  Minji Jo; Shinako Takimoto; Valerie Montel; Steven L Gonias
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.